Review Reports
- Marina Makarova 1,2,3,
- Gulsara Baimakanova 1,4,* and
- Natalia Bodunova 4
- et al.
Reviewer 1: Anonymous Reviewer 2: Anonymous Reviewer 3: Barbara Ruaro
Round 1
Reviewer 1 Report
Comments and Suggestions for AuthorsThis manuscript is well written to describe the diagnostic value of VEGF-D in LAM patients in Russian Federation for the first time. The major finding of this work is that the international recommendation of diagnosis cut-off point of 800 pg/ml was applicable in Russian also. I have a few suggestions to improve the manuscript.
- Please describe the diagnoses of the patients in non-LAM group.
- Line 59, mam-malian=mammalian.
- Line 61, cells cells=cells.
- Figure 1: less than 799, should be less than 800.
- Table 1: Three patients in non-LAM group presented with extrapulmonary manifestations (renal angiomyolipoma, lymphangioleiomyoma, lymphadenopathy), what are their diagnosis. How did the authors exclude the LAM diagnosis?
Author Response
Response to reviewers’ comments on the manuscript by Marina Makarova entitled “Diagnostic Value of Serum VEGF D in Lymphangioleiomy-omatosis: Results of the First Prospective Study in the Russian Federation”
General Comment:
This manuscript is well written to describe the diagnostic value of VEGF-D in LAM patients in Russian Federation for the first time. The major finding of this work is that the international recommendation of diagnosis cut-off point of 800 pg/ml was applicable in Russian also. I have a few suggestions to improve the manuscript
Response:
We thank the reviewer for the positive assessment of our work and for acknowledging the relevance of evaluating the diagnostic performance of VEGF-D in patients with lymphangioleiomyomatosis in the Russian Federation. We also appreciate the recognition that the internationally recommended diagnostic cut-off value of 800 pg/mL is applicable to our study population. We have carefully considered all subsequent comments and revised the manuscript accordingly to further improve its clarity, methodological transparency, and clinical relevance. Detailed responses to each suggestion are provided below.
Comment 1.
Please describe the diagnoses of the patients in non-LAM group.
Response
To improve the transparency of the study design and the composition of the comparison group, we have provided a detailed description of the diagnoses and diagnostic status of patients included in the non-LAM group in the Supplementary Materials (Supplementary Table S1).
Briefly, the non-LAM group included patients with alternative causes of cystic lung disease or cyst-like changes on HRCT. Specifically, this group comprised patients with morphologically verified pulmonary emphysema, sarcoidosis, and thoracic endometriosis; patients with Birt–Hogg–Dubé syndrome confirmed by pathogenic mutations in the FLCN gene; and one patient with lymphocytic interstitial pneumonia associated with Sjögren’s syndrome. In addition, several patients were either undergoing further diagnostic evaluation, declined morphological verification, or did not undergo invasive diagnostic procedures because morphological verification was not clinically justified due to minimal structural lung involvement without functional impairment.
The detailed breakdown of diagnoses and the corresponding diagnostic confirmation methods are provided in Supplementary Table S1.
Comment 2.
Line 59, mam-malian=mammalian.
Response
Done
Comment 3.
Line 61, cells cells=cells.
Response
Done
Comment 4.
Figure 1: less than 799, should be less than 800.
Response
We thank the reviewer for this observation. To avoid any ambiguity related to category labeling around the 800 pg/mL diagnostic threshold, we revised Figure 1 and replaced the previous categorical presentation with a box-and-whisker plot showing the full distribution of serum VEGF-D values in the non-LAM and LAM groups. This revision eliminates the “<799 vs <800” labeling issue and improves clarity by presenting median, interquartile range, and outliers; the statistical significance of the between-group comparison is displayed on the figure. The updated caption reads: “Figure 1. Serum VEGF-D in patients with and without LAM. Box plots indicate the median and interquartile range, whiskers represent the most extreme values within 1.5 interquartile ranges, and circles denote outliers. The p value for the between-group comparison is shown in the figure (p < 0.0001).”
Comment 5.
Table 1: Three patients in non-LAM group presented with extrapulmonary manifestations (renal angiomyolipoma, lymphangioleiomyoma, lymphadenopathy), what are their diagnosis. How did the authors exclude the LAM diagnosis?
Response
We thank the reviewer for this important clarification request. We have revised Table 1 by adding a footnote specifying the diagnoses of the non-LAM patients who presented with extrapulmonary manifestations. In our cohort, three non-LAM patients had renal angiomyolipoma. Their final diagnoses were as follows: one patient had Birt–Hogg–Dubé syndrome confirmed by pathogenic FLCN mutation, one patient had thoracic endometriosis with morphological verification, and one patient had pulmonary emphysema with morphological verification.
Reviewer 2 Report
Comments and Suggestions for AuthorsThis manuscript entitled “Diagnostic Value of Serum VEGF D in Lymphangioleiomyomatosis: Results of the First Prospective Study in the Russian Federation” presents the first prospective evaluation of serum VEGF-D as a diagnostic biomarker for lymphangioleiomyomatosis (LAM) in the Russian Federation. The topic is clinically relevant and timely, as VEGF-D is currently the most validated non-invasive biomarker for LAM and its implementation in regions where testing has only recently become available is of clear practical importance. The study is well aligned with international diagnostic guidelines and addresses an evident gap in regional data.
The authors demonstrate that serum VEGF-D shows good diagnostic accuracy in women with multiple pulmonary cysts, with findings largely consistent with previously published international cohorts. The prospective design and standardized preanalytical handling of samples are notable strengths.
However, several issues should be addressed before the manuscript can be accepted for publication. These include clarification of methodological aspects, improvement of language and style, correction of redundancies and minor inconsistencies, and a more critical discussion of limitations and generalizability.
Major Comments
Redundancy in the Introduction
The description of the pathogenesis of LAM related to TSC gene deletion and mTOR pathway activation is repeated almost verbatim (lines 55–60). This redundancy should be removed to improve readability and conciseness.
Clarification of Non-LAM Diagnoses
The manuscript states that the non-LAM group included patients with emphysema, sarcoidosis, and endometriosis, while in many cases the etiology of cystic lung disease remained unclear. A more detailed breakdown of confirmed alternative diagnoses and the diagnostic criteria used for them would strengthen the interpretation of specificity and reduce potential diagnostic ambiguity.
Threshold Selection and Clinical Implications
The authors identify 738 pg/mL as the optimal VEGF-D cut-off in their cohort based on ROC analysis, while international guidelines recommend 800 pg/mL. The clinical implications of using a lower threshold should be discussed in more depth, particularly regarding potential false positives and how this might affect clinical decision-making in routine practice.
Histological Confirmation
Although the study follows current guidelines that do not require histology in all cases, the absence of histological confirmation in a subset of patients should be discussed more critically. The authors should clarify how many LAM diagnoses were based solely on imaging and extrapulmonary features and whether this could have influenced diagnostic accuracy estimates.
Generalizability and Sample Size
The relatively small, single-center cohort limits generalizability. While this is acknowledged in the limitations section, the authors should further discuss how regional referral patterns or disease phenotypes may differ from larger international cohorts.
Minor Comments
Language and Style
The manuscript would benefit from careful English language editing. There are multiple grammatical errors, awkward phrasings, and inconsistent hyphenation (e.g., “VEGF D” vs. “VEGF-D”, “mam-malian”). Consistent terminology should be used throughout.
Figure Quality and Legends
Figure 1 and Figure 2 should have clearer legends and improved labeling. In Figure 1, the y-axis labeling and terminology (“certain level of LAM”) are unclear and should be revised for precision.
Statistical Reporting
P-values should be reported consistently (e.g., exact values where possible rather than only “p < 0.0001”). Additionally, confidence intervals for sensitivity and specificity could further strengthen the diagnostic analysis.
Table Formatting
Table 1 would benefit from clearer alignment and consistent decimal formatting. Abbreviations should be defined either in the table footnote or consistently in the main text.
References and Minor Typos
Several references contain minor formatting issues, and there are typographical errors throughout the manuscript. A final thorough proofreading is recommended.
Comments on the Quality of English LanguageLanguage and Style
The manuscript would benefit from careful English language editing. There are multiple grammatical errors, awkward phrasings, and inconsistent hyphenation (e.g., “VEGF D” vs. “VEGF-D”, “mam-malian”). Consistent terminology should be used throughout.
Author Response
Response to reviewers’ comments on the manuscript by Marina Makarova entitled “Diagnostic Value of Serum VEGF D in Lymphangioleiomy-omatosis: Results of the First Prospective Study in the Russian Federation”
General Comment:
This manuscript entitled “Diagnostic Value of Serum VEGF D in Lymphangioleiomyomatosis: Results of the First Prospective Study in the Russian Federation” presents the first prospective evaluation of serum VEGF-D as a diagnostic biomarker for lymphangioleiomyomatosis (LAM) in the Russian Federation. The topic is clinically relevant and timely, as VEGF-D is currently the most validated non-invasive biomarker for LAM and its implementation in regions where testing has only recently become available is of clear practical importance. The study is well aligned with international diagnostic guidelines and addresses an evident gap in regional data.
The authors demonstrate that serum VEGF-D shows good diagnostic accuracy in women with multiple pulmonary cysts, with findings largely consistent with previously published international cohorts. The prospective design and standardized preanalytical handling of samples are notable strengths.
However, several issues should be addressed before the manuscript can be accepted for publication. These include clarification of methodological aspects, improvement of language and style, correction of redundancies and minor inconsistencies, and a more critical discussion of limitations and generalizability.
Response:
We thank the reviewer for the thorough evaluation of our manuscript and for highlighting its clinical relevance and practical importance for the Russian Federation, where VEGF-D testing has only recently become available. We appreciate the positive assessment of the prospective design, the standardized preanalytical sample handling, and the overall consistency of our findings with previously published international cohorts.
We fully agree that several aspects require improvement prior to publication. In response, we have revised the manuscript to improve methodological clarity, language and style, and internal consistency. We also expanded the discussion to provide a more critical appraisal of the study limitations, including potential sources of selection bias, the composition and diagnostic heterogeneity of the non-LAM comparator group, and factors affecting generalizability to other clinical settings. Specific changes include removal of redundant text, harmonization of terminology and cut-off reporting, and additional details regarding diagnostic adjudication and statistical reporting.
We provide detailed, point-by-point responses to each of the reviewer’s comments below and indicate the corresponding changes in the revised manuscript.
Comment 1.
Redundancy in the Introduction
The description of the pathogenesis of LAM related to TSC gene deletion and mTOR pathway activation is repeated almost verbatim (lines 55–60). This redundancy should be removed to improve readability and conciseness.
Response
We thank the reviewer for this observation. We agree that this section was redundant. The duplicated description of LAM pathogenesis related to TSC gene inactivation and mTOR pathway activation has been removed from the Introduction to improve readability and conciseness.
Comment 2.
Clarification of Non-LAM Diagnoses
The manuscript states that the non-LAM group included patients with emphysema, sarcoidosis, and endometriosis, while in many cases the etiology of cystic lung disease remained unclear. A more detailed breakdown of confirmed alternative diagnoses and the diagnostic criteria used for them would strengthen the interpretation of specificity and reduce potential diagnostic ambiguity.
Response:
We thank the reviewer for this important suggestion and agree that a more detailed characterization of the non-LAM group improves interpretability of specificity estimates and reduces potential diagnostic ambiguity. We have therefore expanded the description of the non-LAM cohort and provided a complete diagnostic breakdown with the corresponding confirmation methods in the Supplementary Materials (Supplementary Table S1).
Briefly, the non-LAM group included morphologically verified pulmonary emphysema, sarcoidosis, and thoracic endometriosis, Birt–Hogg–Dubé syndrome confirmed by pathogenic FLCN mutations, and lymphocytic interstitial pneumonia associated with Sjögren’s syndrome. In addition, a subset of patients were still undergoing diagnostic workup or did not undergo morphological verification either due to patient refusal or because invasive verification was not clinically justified in the setting of minimal structural lung involvement without functional impairment.
Comment 3.
Threshold Selection and Clinical Implications
The authors identify 738 pg/mL as the optimal VEGF-D cut-off in their cohort based on ROC analysis, while international guidelines recommend 800 pg/mL. The clinical implications of using a lower threshold should be discussed in more depth, particularly regarding potential false positives and how this might affect clinical decision-making in routine practice.
Response
We thank the reviewer for this important comment. We agree that the cohort-derived threshold of 738 pg/mL should be interpreted cautiously. We emphasize that this value reflects ROC optimization in our single-center prospective cohort and represents the first such estimate reported for the Russian Federation, rather than a proposed replacement for the internationally recommended diagnostic threshold of 800 pg/mL. In the revised manuscript, we clarified that 800 pg/mL remains the preferred diagnostic cut-off for routine practice, while lower thresholds may increase sensitivity at the expense of reduced specificity and a higher false-positive rate. We also added text to the Discussion and Limitations addressing the potential clinical consequences of lowering the threshold, including unnecessary additional investigations in non-LAM patients, and we note that any alternative cut-offs require external validation in larger and multicenter cohorts before clinical implementation.
Comment 4
Histological Confirmation
Although the study follows current guidelines that do not require histology in all cases, the absence of histological confirmation in a subset of patients should be discussed more critically. The authors should clarify how many LAM diagnoses were based solely on imaging and extrapulmonary features and whether this could have influenced diagnostic accuracy estimates.
Response
We thank the reviewer for this important point and agree that the extent of histological confirmation and its potential impact should be more explicitly addressed. We have clarified the basis for the LAM diagnosis in the manuscript and expanded the Discussion to more critically acknowledge limitations related to incomplete histological verification.
In our cohort of 48 patients with definite LAM, the diagnosis was confirmed by surgical lung biopsy in 15 patients, which corresponds to 31 percent. Among the remaining patients diagnosed without lung biopsy, 28 had serum VEGF-D concentrations of 800 pg/mL or higher. Within this subgroup, 23 patients had additional confirmatory features consistent with current diagnostic recommendations, including tuberous sclerosis complex in 1 patient, recurrent chylothorax in 2 patients, renal angiomyolipomas in 11 patients identified by ultrasound and or CT with morphological verification in 3 cases, and lymphangioleiomyomas and or retroperitoneal lymphadenopathy in 9 patients identified by ultrasound and or CT with morphological verification in 2 cases. Only 5 women were diagnosed based on a typical HRCT pattern for LAM in combination with VEGF-D of 800 pg/mL or higher without other documented extrapulmonary features. Overall, these data indicate that the majority of LAM diagnoses in our cohort could be established without lung biopsy, which aligns with contemporary guideline-based practice, while we now explicitly discuss the potential for diagnostic misclassification in non-biopsied cases and its implications for diagnostic accuracy estimates.
Comment 5
Generalizability and Sample Size. The relatively small, single-center cohort limits generalizability. While this is acknowledged in the limitations section, the authors should further discuss how regional referral patterns or disease phenotypes may differ from larger international cohorts.
Response
We thank the reviewer for this important comment and agree that the single-center design and sample size may limit external validity. We have expanded the Limitations section to more explicitly discuss the potential influence of regional referral patterns and local case mix. Specifically, we note that a tertiary referral center may be enriched for diagnostically complex patients with a higher pre-test probability of LAM compared with unselected populations presenting with incidental cystic lung changes, which could affect diagnostic performance estimates. We also added that differences in phenotype distribution, including the proportion of sporadic versus TSC-associated LAM, as well as local access to VEGF-D testing and diagnostic workup pathways, may further limit direct extrapolation to other settings and larger international cohorts.
Comment 6
The manuscript would benefit from careful English language editing. There are multiple grammatical errors, awkward phrasings, and inconsistent hyphenation (e.g., “VEGF D” vs. “VEGF-D”, “mam-malian”). Consistent terminology should be used throughout.
Response
We thank the reviewer for this suggestion and agree that language quality and consistency are essential for clarity. The manuscript has undergone comprehensive English language editing to correct grammatical errors and awkward phrasing, and to improve overall readability. We also standardized terminology and hyphenation throughout the text, tables, and figures, including consistent use of “VEGF-D” and correction of typographical errors such as “mam-malian”.
Comment 7
Figure 1 and Figure 2 should have clearer legends and improved labeling. In Figure 1, the y-axis labeling and terminology (“certain level of LAM”) are unclear and should be revised for precision.
Response
We thank the reviewer for this helpful suggestion and agree that the original figure labeling could be improved for clarity and precision. We revised the legends and axis labels for both Figure 1 and Figure 2. In Figure 1, we replaced the ambiguous wording, removed the term “certain level of LAM”, and updated the y-axis label to explicitly indicate the proportion of patients. We also harmonized terminology and units across both figures to ensure consistent presentation.
Comment 8
P-values should be reported consistently (e.g., exact values where possible rather than only “p < 0.0001”). Additionally, confidence intervals for sensitivity and specificity could further strengthen the diagnostic analysis.
Response
We thank the reviewer for these suggestions. Regarding p-values, we agree that consistent reporting is important. In the current manuscript, very small p-values are reported as threshold values (for example, p < 0.0001) to avoid implying a level of precision that is not clinically meaningful and to maintain readability, given that these values are far below conventional significance levels and do not affect interpretation of the findings. We have reviewed the manuscript to ensure that the reporting format is applied consistently across sections.
With respect to confidence intervals for sensitivity and specificity, we agree that they can provide additional information on estimate precision. In this study, the primary emphasis was placed on ROC analysis and the AUC as the main summary measure of diagnostic performance, and we therefore presented point estimates for operating characteristics at the selected thresholds. We now explicitly acknowledge in the Limitations that reporting confidence intervals for sensitivity and specificity would further strengthen the diagnostic analysis and should be considered in larger validation studies.
Comment 9
Table 1 would benefit from clearer alignment and consistent decimal formatting. Abbreviations should be defined either in the table footnote or consistently in the main text.
Response
We thank the reviewer for these practical suggestions. We have revised Table 1 to improve alignment and readability and have standardized decimal formatting throughout the table. In addition, we ensured that all abbreviations used in Table 1 are defined consistently, either in the table footnote and or in the main text, in accordance with the journal’s style requirements.
Comment 10
Several references contain minor formatting issues, and there are typographical errors throughout the manuscript. A final thorough proofreading is recommended.
Response
We thank the reviewer for this recommendation. We performed a thorough proofreading of the entire manuscript and corrected typographical and stylistic errors throughout. We also reviewed the reference list in detail and corrected minor formatting inconsistencies to ensure uniformity and compliance with the journal’s requirements.
Reviewer 3 Report
Comments and Suggestions for Authors The topic is interesting. The paper is quite well written. This study evaluated the effectiveness of serum VEGF-D as a diagnostic biomarker for lymphangioleiomyomatosis (LAM) in women with multiple lung cysts. In a cohort of 71 women, those with LAM had significantly higher VEGF-D levels than those without the disease. The test showed high accuracy, with an area under the curve of 0.866, and a threshold of 738 pg/mL provided good sensitivity and specificity. These findings suggest that VEGF-D testing is a valuable noninvasive tool for diagnosing LAM and could be incorporated into routine clinical practice in Russia. I have some suggestions: 1- Abstract. I suggest authors to consider simplifying complex sentences and removing redundant information to make the abstract more concise and easier to read. For example, specify the key findings upfront and streamline methodological details to focus on the most relevant aspects. 2- The abstract would benefit from a more detailed description of the statistical methods used to determine the optimal VEGF-D cut-off value, including whether Youden's index or another criterion was employed, to enhance reproducibility and clarity of the diagnostic threshold selection process. 3- Including additional performance metrics such as positive predictive value (PPV), negative predictive value (NPV), or likelihood ratios at the identified cut-off points would provide a more comprehensive assessment of VEGF-D's diagnostic utility and facilitate clinical decision-making.4- I suggest authors to emphasize how the findings could impact clinical practice, such as suggesting specific recommendations for incorporating VEGF-D testing into diagnostic protocols or discussing potential benefits over existing methods.
5- Some sections (introduction, methods, results) contain repetitive information, such as the explanation of the TSC gene deletion leading to mTOR pathway activation. Streamlining these parts by consolidating similar ideas will improve readability and make the narrative more concise. For example, combine or eliminate duplicate sentences about TSC gene deletion and mTOR activation to maintain focus and clarity.
6- The article covers various complex topics—from pathogenesis to diagnostic criteria—without clear subsection transitions. Consider reorganizing the manuscript into well-defined sections with subheadings (e.g., "Introduction," "Pathogenesis," "Diagnostic Methods," "Serum VEGF-D as a Biomarker," "Study Methods," "Results," "Discussion"). This will guide readers more effectively through the content and highlight the logical progression of ideas.
7- While the statistical results are presented, including more detailed interpretation of the clinical significance of findings—such as the implications of the ROC curve's area under the curve (AUC=0.866), sensitivity, and specificity—would enhance understanding. Additionally, adding confidence intervals and discussing potential limitations (e.g., sample size, generalizability) can provide a more balanced perspective on the diagnostic utility of VEGF-D in this context.
8- Discussion. To improve readability, consider dividing the discussion into clearly labeled subsections, such as "Diagnostic Utility," "Factors Influencing VEGF D Levels," and "Limitations and Future Directions." This will help guide readers through the complex information and emphasize key points more effectively.
9- Discussion. While the section mentions some limitations, expanding this part to include a more detailed discussion of how these limitations may impact the interpretation of results—and proposing specific strategies to address them in future studies—would add depth and rigor to the discussion.
Author Response
Response to reviewers’ comments on the manuscript by Marina Makarova entitled “Diagnostic Value of Serum VEGF D in Lymphangioleiomy-omatosis: Results of the First Prospective Study in the Russian Federation”
General Comment:
The topic is interesting. The paper is quite well written. I have some suggestions:
Response:
We thank the reviewer for the positive assessment of the manuscript. We appreciate the reviewer’s time and constructive suggestions. We have carefully considered each of the comments provided below and revised the manuscript accordingly to improve clarity, methodological transparency, and overall presentation.
Comment 1
1- Abstract. I suggest authors to consider simplifying complex sentences and removing redundant information to make the abstract more concise and easier to read. For example, specify the key findings upfront and streamline methodological details to focus on the most relevant aspects.
Response
We thank the reviewer for this helpful suggestion. We revised the abstract to improve readability and conciseness by simplifying complex sentences, removing redundant phrasing, and streamlining methodological details. We also reorganized the text to present the key findings more clearly while maintaining the required structured format (Background/Objectives, Methods, Results, Conclusions).
Comment 3
I suggest authors to emphasize how the findings could impact clinical practice, such as suggesting specific recommendations for incorporating VEGF-D testing into diagnostic protocols or discussing potential benefits over existing methods.
Response
We thank the reviewer for this valuable suggestion. We revised the Conclusions to more explicitly highlight the practical implications of our findings and to provide clear, clinically actionable recommendations on how serum VEGF-D testing can be incorporated into routine diagnostic pathways. Specifically, we added guidance on using VEGF-D testing prior to lung biopsy in patients with typical HRCT findings and clinical suspicion of LAM when other confirmatory features are absent, and we clarified that morphological verification should be considered when HRCT findings are atypical and cystic lung disease is the only manifestation.
Comment 4
Some sections (introduction, methods, results) contain repetitive information, such as the explanation of the TSC gene deletion leading to mTOR pathway activation. Streamlining these parts by consolidating similar ideas will improve readability and make the narrative more concise. For example, combine or eliminate duplicate sentences about TSC gene deletion and mTOR activation to maintain focus and clarity.
Response
We thank the reviewer for this suggestion and agree that these repetitions reduced readability. We reviewed the manuscript for duplicated explanations of TSC gene inactivation and mTOR pathway activation and streamlined the text by removing redundant sentences and consolidating the remaining content into a single, concise description. This revision was applied across the relevant sections to improve narrative flow and clarity.
Comment 5
The article covers various complex topics—from pathogenesis to diagnostic criteria—without clear subsection transitions. Consider reorganizing the manuscript into well-defined sections with subheadings (e.g., "Introduction," "Pathogenesis," "Diagnostic Methods," "Serum VEGF-D as a Biomarker," "Study Methods," "Results," "Discussion"). This will guide readers more effectively through the content and highlight the logical progression of ideas.
Response
We thank the reviewer for this constructive recommendation. We reorganized the manuscript to improve structure and readability by introducing clearer subsection transitions and adding informative subheadings that reflect the logical flow of the narrative. In particular, we separated background mechanistic content from diagnostic considerations and revised the section layout to make the progression from pathogenesis and diagnostic criteria to biomarker rationale, study methods, results, and discussion more explicit.
Comment 6
While the statistical results are presented, including more detailed interpretation of the clinical significance of findings—such as the implications of the ROC curve's area under the curve (AUC=0.866), sensitivity, and specificity—would enhance understanding. Additionally, adding confidence intervals and discussing potential limitations (e.g., sample size, generalizability) can provide a more balanced perspective on the diagnostic utility of VEGF-D in this context.
Response
We thank the reviewer for this helpful suggestion. We revised the manuscript to provide a clearer clinical interpretation of the diagnostic performance metrics, including the implications of the AUC, sensitivity, and specificity in routine practice. Specifically, we added text describing how the cohort-derived threshold relates to the guideline-recommended 800 pg/mL cut-off and highlighted that a small subset of patients with definite LAM may have VEGF-D values below 800 pg/mL despite typical HRCT findings and independent confirmatory evidence. We also expanded the Limitations section to further address sample size and single-center generalizability. Confidence intervals for the AUC are provided, and we acknowledge that presenting confidence intervals for sensitivity and specificity would further strengthen precision estimates in future larger validation cohorts.
Comment 6
Discussion. To improve readability, consider dividing the discussion into clearly labeled subsections, such as "Diagnostic Utility," "Factors Influencing VEGF D Levels," and "Limitations and Future Directions." This will help guide readers through the complex information and emphasize key points more effectively.
Response
We thank the reviewer for this constructive recommendation. We revised the Discussion to improve structure and readability by introducing clearly labeled subsections. In particular, we added dedicated subsections titled “Diagnostic Utility” and “Study limitations” which better separate interpretation of diagnostic performance from study constraints and implications for further research.
Comment 7
Discussion. While the section mentions some limitations, expanding this part to include a more detailed discussion of how these limitations may impact the interpretation of results—and proposing specific strategies to address them in future studies—would add depth and rigor to the discussion.
Response
We thank the reviewer for this valuable suggestion. We expanded the Limitations section to more explicitly describe how key constraints, including the single-center design, sample size, and diagnostic heterogeneity of the non-LAM group, may influence interpretation of diagnostic performance and generalizability. We also added brief, concrete directions for future research, emphasizing the need for larger multicenter cohorts, external validation of thresholds, and more comprehensive reporting of precision measures in subsequent studies.
Round 2
Reviewer 1 Report
Comments and Suggestions for AuthorsMy comments have been revised accordingly.
I did not see the online supplementary files. Please check the changes for me.
Reviewer 3 Report
Comments and Suggestions for AuthorsThe authors edited the manuscript and took my suggestions into account. I have no further comments.